Group
Biotech
11 themes97 tickers
10D rank10D#166of 172 groups/172
Dive into Biotech, where we explore everything from established pharma giants and cutting-edge GLP-1 therapies to revolutionary oncology, genetic medicine, and AI-driven drug discovery. Understand what's going on in health innovation!
GLP1-6.87%9.1%
Oncology+28.91%9.1%
Pharma/Therapeutics+6.07%9.1%
Commercial / Late Stage-2.36%9.1%
Neurology, CNS & Rare Disorders+16.53%9.1%
Oncology & Immunotherapy+60.74%9.1%
RNA-Based/Genetic Medicine+58.65%9.1%
AI Driven Drug Discovery+72.97%9.1%
Established Pharma+24.88%9.1%
Psychedelic Drugs+34.26%9.1%
Scalable Oncology Drugs+16.90%9.1%
As of Oct 9, 2026, 4:20 AM ET
Themes in this group
| Biotech '24: OncologyOncology | 8 | $4.14B | $33.10B | +0.92% | +0.62% | -0.12% | -0.52% | +45.59% | +28.91% | +83.26% | -8.17% | +15.03% | +33.71% | +26.65% | +107.36% | +9.50% | +32.28% |
| Biotech '25: Neurology, CNS & Rare DisordersNeurology, CNS & Rare Disorders | 7 | $1.27B | $8.88B | +0.63% | -1.25% | -1.83% | -0.03% | +6.17% | +16.53% | +44.42% | +218.52% | -0.86% | +8.12% | +1.87% | +90.77% | -2.72% | -0.75% |
| Biotech '25: Commercial / Late StageCommercial / Late Stage | 5 | $5.29B | $26.45B | +1.30% | -1.79% | -6.38% | +0.66% | -13.58% | -2.36% | +26.51% | +92.65% | -8.26% | -3.18% | -6.60% | +16.84% | +10.80% | -3.32% |
| Biotech '26: Established PharmaEstablished Pharma | 10 | $192.27B | $1.92T | -0.30% | -3.05% | -2.05% | -0.73% | +12.37% | +24.88% | +24.81% | +63.50% | -4.92% | +14.07% | +5.27% | +35.24% | +2.99% | +3.41% |
| Biotech '26: Scalable Oncology DrugsScalable Oncology Drugs | 12 | $17.68B | $212.19B | -2.23% | -4.36% | -16.77% | -1.41% | -0.57% | +16.90% | +28.72% | +78.21% | -13.85% | -1.61% | +0.57% | +50.86% | +3.33% | -5.38% |
| Biotech '25: Oncology & ImmunotherapyOncology & Immunotherapy | 12 | $5.74B | $68.87B | -1.11% | -5.77% | -11.26% | -3.78% | +23.42% | +60.74% | +76.96% | +162.99% | -5.97% | +19.09% | +21.15% | +114.80% | +3.02% | -3.07% |
| Biotech '24: Pharma/TherapeuticsPharma/Therapeutics | 13 | $3.67B | $47.70B | +0.57% | -5.79% | -13.26% | -2.38% | -4.46% | +6.07% | +29.79% | +112.13% | -13.68% | +6.18% | -6.64% | +59.86% | +11.01% | -6.54% |
| Biotech '26: AI Driven Drug DiscoveryAI Driven Drug Discovery | 18 | $89.81B | $1.62T | -1.59% | -6.28% | +4.81% | -5.11% | +68.81% | +72.97% | +100.96% | +53.30% | +6.66% | +44.07% | +57.98% | +121.00% | +5.45% | +3.55% |
| Biotech '25: RNA-Based/Genetic MedicineRNA-Based/Genetic Medicine | 7 | $4.24B | $29.67B | -0.99% | -9.99% | -18.06% | -6.68% | +38.46% | +58.65% | +59.22% | +93.59% | -18.39% | +18.18% | +23.67% | +246.39% | +2.64% | -0.48% |
| Biotech '26: Psychedelic DrugsPsychedelic Drugs | 11 | $748.7M | $8.24B | -0.65% | -11.23% | -12.57% | -6.14% | +57.01% | +34.26% | +59.58% | -22.02% | -7.33% | +37.27% | +54.61% | +104.24% | +6.02% | -22.61% |
| Biotech '24: GLP1GLP1 | 4 | $7.77B | $31.06B | -3.37% | -11.69% | -19.34% | -6.70% | -18.63% | -6.87% | -11.41% | +387.88% | -18.49% | -4.37% | -14.42% | +27.03% | +3.60% | -8.82% |
Default: 10D ↓ · Click headers to sort · Shift+click secondary